REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Results & Progress
9

AOD-9604 Results — Honest Assessment

Hawk Cho·about 2 months ago
Giving my honest AOD-9604 results because I think this community needs more realistic reports alongside the glowing reviews. Background: 42-year-old, moderately active, primary goals were recovery and general health optimization. Positives: Sleep improved meaningfully. This was the most consistent and obvious benefit. I also noticed better recovery from workouts, though this is harder to quantify objectively. Joint comfort improved — morning stiffness that I attributed to age decreased noticeably. Neutrals: mood and energy had minor improvements that could also be attributed to better sleep. Hard to isolate causation. Negatives: cost is significant. Injection site irritation was annoying for the first few weeks. The daily routine of reconstitution, dosing, and tracking takes more time and mental energy than I expected. Overall verdict: AOD-9604 delivered on its primary claims for me, but the magnitude of effects was moderate, not transformative. If your expectations are calibrated for a 15-20 percent improvement in target areas rather than a complete overhaul, you will probably be satisfied.

Comments (4)

Dylan ChaseDEMO·about 2 months ago

This matches my experience with AOD-9604 almost exactly. The timeline you describe — subtle at first, then clearly noticeable by week 4-5 — is very typical from what I have seen across multiple reports. For anyone reading this and feeling impatient in the first couple weeks, stick with it. The effects are cumulative and take time to establish.

5
Jamie CooperDEMO·about 2 months ago

Appreciate the honest assessment. Too many AOD-9604 reviews read like advertisements. The moderate but meaningful improvement you describe is exactly what I experienced as well. I think the community benefits more from realistic reports like this than from overhyped claims.

2
Scout BarkerDEMO·about 2 months ago

Question for you: did you get bloodwork done before and during your AOD-9604 protocol? I am about to start and trying to decide which panels to run. Obviously the basics but curious if there are any specific markers that are particularly informative for tracking AOD-9604 response.

3
Aria FrancoDEMO·about 2 months ago

I ran AOD-9604 at a slightly higher dose than what you used and found the results were actually about the same. This lines up with the dose-response data suggesting there is a ceiling effect. Higher dose just meant more injection site irritation without additional benefit. Your approach seems well-calibrated.

4

Sign in to comment.